ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 778

PTPN22 rs2476601 and Susceptibility to Biopsy Proven Giant Cell Arteritis (GCA) in an Australian Sample

Susan Lester1, Alex Hewitt2, Linda Bradbury3, Elisabeth De Smit4, Andrew Harrison5, Graeme Jones6, Geoffrey O. Littlejohn7, Tony R. Merriman8, Bain Shenstone9, Malcolm D. Smith10, Maureen Rischmueller11, Matthew A. Brown12 and Catherine L. Hill13,14, 1Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, 2Lions Eye Institute, University of Western Australia, Perth, Australia, 3The University of Queensland, Brisbane, Australia, 4Centre for Eye Research, University of Melbourne, Melbourne, Australia, 5Medicine, University of Otago, Wellington, New Zealand, 6Menzies Research Institute Tasmania, University of Tasmania, HOBART, Australia, 7Rheumatology, Monash Medical Center, Melbourne, Australia, 8Department of Biochemistry, University of Otago, Dunedin, New Zealand, 9Concord Hospital, Sydney, Australia, 10Rheumatology Research Unit, Repatriation General Hospital, Adelaide SA, Australia, 11Department of Rheumatology, The Queen Elizabeth Hospital, SA, Australia, 12University of Queensland Diamantina Institute, Brisbane, Australia, 13Discipline of Medicine, University of Adelaide, Adelaide, Australia, 14Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: giant cell arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The aetiology and genetic background of GCA remains unclear, although genetic susceptibility is known to play a role. Recently, an association with the minor, loss of function, allele of PTPN22 rs2476601 (R620W), was reported in a Spanish cohort of biopsy-proven GCA (odds ratio = 1.62, 95%CI 1.29-2.04, p = 0.0001)1. Therefore, dysregulation of TCR signalling may be implicated in the pathogenesis of GCA. The aim of this study was to determine the association between the PTPN22 rs2476601 minor (A) allele and biopsy-proven GCA in an Australian cohort.

Methods: rs2476601 genotyping was performed by a Taqman assay (C-16021387, Applied Biosystems) in 209 GCA cases. Genotype data from 1407 healthy ethnically-matched unrelated postmenopausal women included in the Anglo-Australian Osteoporosis Genetics Consortium study of bone density variation were used as healthy controls. All GCA cases were temporal artery biopsy proven, and were recruited in Australia by the Arthritis Genomics Recruitment Initiative in Australasia (AGRIA). The mean age of GCA patients at diagnosis was 73 yrs (SE 8 yrs), with 68% female.

Results: The frequency of the A allele was 0.093 in GCA cases and 0.103 in the controls. Overall, there was no evidence of an association between GCA and controls, (OR=0.89, 95% CI 0.63, 1.27, p = 0.52). A random effects meta-analysis of replication datasets from Germany1, Norway1, UK1, and Australia, included 769 GCA patients and 14,214 controls, did not reach statistical significance (OR 1.21, 95% CI 0.73, 2.00, p = 0.32). Similarly, a random effects meta-analysis which included the original Spanish dataset (1,392 GCA cases and 15,943 controls), also did not reach statistical significance (OR 1.31, 95% CI 0.90, 1.90, p = 0.11), Figure 1.

Conclusion: There was no statistically significant association between PTPN22 rs2476601 in this Australian GCA cohort. Nor does a meta-analysis of combined, available data reach statistical significance. However, an association with small effect size cannot yet be definitively excluded, and further studies may be required.

1.       Serrano et al. Ann Rheum Dis 2013;72:1882-6.

Figure 1. Random Effects Meta-Analysis for the association between PTPN22 rs2476601 A allele and Giant Cell Arteritis


Disclosure:

S. Lester,
None;

A. Hewitt,
None;

L. Bradbury,
None;

E. De Smit,
None;

A. Harrison,
None;

G. Jones,
None;

G. O. Littlejohn,
None;

T. R. Merriman,
None;

B. Shenstone,
None;

M. D. Smith,
None;

M. Rischmueller,
None;

M. A. Brown,
None;

C. L. Hill,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ptpn22-rs2476601-and-susceptibility-to-biopsy-proven-giant-cell-arteritis-gca-in-an-australian-sample/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology